These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 18927285)

  • 1. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
    Yang M; Shan B; Li Q; Song X; Cai J; Deng J; Zhang L; Du Z; Lu J; Chen T; Wery JP; Chen Y; Li Q
    Int J Cancer; 2013 Jan; 132(2):E74-84. PubMed ID: 22948846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
    Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
    Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
    Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
    Endo H; Okami J; Okuyama H; Kumagai T; Uchida J; Kondo J; Takehara T; Nishizawa Y; Imamura F; Higashiyama M; Inoue M
    J Thorac Oncol; 2013 Feb; 8(2):131-9. PubMed ID: 23328545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
    Zhang XC; Zhang J; Li M; Huang XS; Yang XN; Zhong WZ; Xie L; Zhang L; Zhou M; Gavine P; Su X; Zheng L; Zhu G; Zhan P; Ji Q; Wu YL
    J Transl Med; 2013 Jul; 11():168. PubMed ID: 23842453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
    Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
    Wang M; Morsbach F; Sander D; Gheorghiu L; Nanda A; Benes C; Kriegs M; Krause M; Dikomey E; Baumann M; Dahm-Daphi J; Settleman J; Willers H
    Cancer Res; 2011 Oct; 71(19):6261-9. PubMed ID: 21852385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
    Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
    J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.